Pharmacyte Biotech Inc.

Company Overview

Business Model: PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies for cancer. Its core technology is the proprietary cellulose-based live cell encapsulation technology, "Cell-in-a-Box®." The current lead product candidate is CypCaps™, which is being developed for pancreatic cancer. The company ceased research and development in diabetes treatment during the year ended April 30, 2024.

Market Position: PharmaCyte Biotech, Inc.'s pancreatic cancer therapy has been granted Orphan Drug status in both the U.S. and the European Union, indicating its potential to address a rare disease with significant unmet medical need. The company's Cell-in-a-Box® capsules are cellulose-based, offering enhanced strength and durability compared to competitors' materials, such as alginate. Encapsulated cells maintain approximately 85% viability after cryopreservation. The U.S. pancreatic cancer market saw an estimated 64,000 diagnoses and 51,000 deaths in 2023.

Recent Strategic Developments: On November 17, 2023, the Board of Directors formed a Strategic Scientific Committee, chaired by Dr. Michael Abecassis, to review business risks and development programs, including the relationship with SG Austria Pte. Ltd. Development program spending has been curtailed pending this review. The company's Investigational New Drug Application (IND) for a pancreatic cancer clinical trial, submitted to the U.S. Food and Drug Administration (FDA) on September 1, 2020, was placed on clinical hold on October 1, 2020. PharmaCyte Biotech, Inc. is actively addressing the FDA's requirements, which include additional sequencing and genetic stability studies, product and Master Cell Bank (MCB) cell stability studies, compatibility evaluation of delivery devices, detailed manufacturing process description, product release specifications, comparability demonstration, biocompatibility assessment, Drug Master File insufficiencies, and an additional nonclinical animal study. The company has completed several of these studies and is in ongoing dialogue with the FDA, seeking to potentially forego the large animal study.

Geographic Footprint: PharmaCyte Biotech, Inc. is headquartered at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169, and maintains storage space in Laguna Hills, California. Its pancreatic cancer therapy holds Orphan Drug status in the U.S. and European Union. Patent applications for the pancreatic cancer product candidate are pending in the U.S., Australia, and Canada, while Melligen cells are patented in the U.S. and Europe.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A (due to $0 revenue)
• Operating Margin: N/A (due to $0 revenue)
• Net Margin: N/A (due to $0 revenue)

Investment in Growth:

• R&D Expenditure: $438,416 (FY2025) / $407,431 (FY2024)
• Strategic Investments:
  • Femasys Inc. (November 14, 2023): Purchased $5,000,000 in senior unsecured convertible notes and warrants.
  • TNF Pharmaceuticals, Inc. (May 20, 2024): Purchased $7,000,000 in Series G Convertible Preferred Stock and warrants.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: In FY2025, PharmaCyte Biotech, Inc. repurchased 1,241,862 shares for $2,567,700 at an average price of $2.0677. As of April 30, 2025, a total of 6,790,437 shares have been repurchased under authorized programs for $17,886,108.
• Dividend Payments: The company paid 4% per annum on its Series B Convertible Preferred Stock. Net dividends recognized were $1,129,759 in FY2025 and $2,517,645 in FY2024.
• Future Capital Return Commitments: The Second Repurchase Program, authorized January 31, 2023, allows for up to an additional $10 million in repurchases, with $2,113,891 remaining available as of April 30, 2025. The program was paused as of April 2025.

Balance Sheet Position:

• Cash and Equivalents: $15,172,163 (2025) / $50,179,968 (2024)
• Total Liabilities: $3,277,284 (2025) / $20,389,264 (2024). This includes warrant liabilities of $338,000 (2025) and $10,784,000 (2024), and derivative liabilities of $0 (2025) and $2,184,000 (2024). The Series B convertible preferred stock, previously subject to redemption, had a value of $0 as of April 30, 2025, down from $11,867,016 in 2024.
• Net Cash Position: $11,894,879 (2025) / $29,790,704 (2024)

Cash Flow Generation:

• Operating Cash Flow: $(2,978,296) (2025) / $(2,151,457) (2024)

Operational Excellence

Production & Service Model: PharmaCyte Biotech, Inc. is focused on the development of cellular therapies for cancer, utilizing its proprietary Cell-in-a-Box® encapsulation technology. The current product candidate, CypCaps™, is designed to deliver therapeutic agents directly to tumor sites. The encapsulation process ensures approximately 85% viability of cells after cryopreservation.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturer: Austrianova - Serves as the sole manufacturer of PharmaCyte Biotech, Inc.'s product candidates. Austrianova has experienced supply chain delays and potential liquidity issues.
• Technology Know-how: SG Austria Pte. Ltd. - Holds the exclusive know-how for the Cell-in-a-Box® technology.

Facility Network:

• Principal Office: 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 (approximately 100 sq ft, month-to-month lease).
• Storage: Rents storage space in Laguna Hills, California.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: PharmaCyte Biotech, Inc. operates within the biotechnology sector, specifically focusing on cellular therapies for cancer. The pancreatic cancer market, its primary target, is characterized by high mortality rates, with an estimated 64,000 diagnoses and 51,000 deaths in the U.S. in 2023. The company's product candidate has Orphan Drug status in key markets, highlighting the significant unmet medical need.

Competitive Positioning Matrix:

Competitive Response Strategy: PharmaCyte Biotech, Inc.'s strategy centers on advancing its lead product candidate, CypCaps™, through the regulatory pathway by diligently addressing the U.S. Food and Drug Administration's clinical hold requirements. The Strategic Scientific Committee has been formed to review and optimize development programs.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Technology Disruption: Foundational Cell-in-a-Box® patents expired in 2017, and the core know-how resides solely with SG Austria Pte. Ltd., posing a potential risk if the relationship with this partner deteriorates or if the technology faces obsolescence.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: PharmaCyte Biotech, Inc. is highly dependent on Austrianova as the sole manufacturer of its product candidates. Austrianova has reported supply chain delays and potential liquidity issues, which could impact the company's development timelines and operational continuity.

Financial & Regulatory Risks

Market & Financial Risks:

• Net Operating Loss Carryforwards: As of April 30, 2025, the company had federal NOLs of approximately $61 million and state NOLs of approximately $31 million, which begin to expire in 2025. An August 2021 ownership change limited the utilization of these NOLs to approximately $24 million federal and $15 million state, with a 100% valuation allowance recorded.

Regulatory & Compliance Risks:

• Industry Regulation: The Investigational New Drug Application (IND) for the pancreatic cancer therapy is currently on clinical hold by the U.S. Food and Drug Administration (FDA). Addressing the FDA's extensive requirements, including additional studies and data, is critical for advancing the product candidate.
• Legal Proceedings: A settlement agreement with H.C. Wainwright & Co., LLC was reached on May 16, 2025, for $1.55 million plus warrants, resulting in a legal settlement expense of $2,019,000 recorded in FY2025.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Cellular Therapies for Cancer: Primary focus on developing CypCaps™ using the Cell-in-a-Box® technology for pancreatic cancer. Investment is directed towards addressing U.S. Food and Drug Administration (FDA) clinical hold requirements, including stability studies, genetic sequencing, biocompatibility, device compatibility, and manufacturing process optimization.
• Diabetes Treatment: Research and development in this area ceased during FY2024.

Intellectual Property Portfolio:

• Patent Strategy: While foundational Cell-in-a-Box® patents (formerly licensed from Bavarian Nordic/GSF) expired on March 27, 2017, PharmaCyte Biotech, Inc. has pending patent applications for its pancreatic cancer product candidate in the U.S., Australia, and Canada, with a potential expiration of March 2038 if issued. Melligen cells are patented in the U.S. and Europe.

Technology Partnerships:

• Strategic Alliances: The company maintains a relationship with SG Austria Pte. Ltd., which holds the know-how for the Cell-in-a-Box® technology. This relationship is currently under review by the Strategic Scientific Committee.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's operations are highly dependent on the Interim Chief Executive Officer and Chief Financial Officer.

Board Composition: The Board of Directors includes four Independent Directors: Jonathan L. Schechter, Robert Weinstein, Wayne R. Walker, and Michael M. Abecassis. Key committees include the Audit Committee (chaired by Robert Weinstein, a financial expert), the Compensation Committee (chaired by Jonathan L. Schechter), and the Nominating Committee (chaired by Wayne R. Walker). Dr. Michael M. Abecassis chairs the Strategic Scientific Committee.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of April 30, 2025, PharmaCyte Biotech, Inc. had two full-time employees.
• Skill Mix: These employees, along with several consultants, are responsible for all research and development activities.

Talent Management: Acquisition & Retention: The company's talent management is highly dependent on its Interim Chief Executive Officer and Chief Financial Officer.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. Food and Drug Administration (FDA): The company's Investigational New Drug Application (IND) for its pancreatic cancer therapy is currently on clinical hold. Compliance with FDA requirements, including additional studies and data, is essential for clinical progression.
• Orphan Drug Status: The pancreatic cancer therapy has been granted Orphan Drug status in both the U.S. and the European Union, providing certain incentives and market exclusivity upon approval.

Legal Proceedings:

• PharmaCyte Biotech, Inc. entered into a Settlement Agreement with H.C. Wainwright & Co., LLC on May 16, 2025, for $1.55 million, along with warrants to purchase common shares. A legal settlement expense of $2,019,000 was recorded in FY2025.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company's effective tax rate is influenced by significant net operating losses and other income/expenses.
• Tax Reform Impact: The One Big Beautiful Bill Act of 2025, enacted July 4, 2025, will allow for immediate expensing of qualifying research and development expenses and permanently extend certain provisions of the Tax Cuts and Jobs Act, effective for the company beginning fiscal 2026. The company is currently evaluating the future impact of these changes.
• Net Operating Loss Carryforwards: As of April 30, 2025, PharmaCyte Biotech, Inc. had federal net operating loss (NOL) carryforwards of approximately $61 million and state NOL carryforwards of approximately $31 million, which begin to expire in 2025. An August 2021 ownership change limited the federal NOLs to approximately $24 million and state NOLs to approximately $15 million. A 100% valuation allowance has been recorded against these deferred tax assets.
• Excise Tax on Stock Repurchases: The company accrued $25,424 in FY2025 and $281,976 in FY2024 for the excise tax on stock repurchases under the Inflation Reduction Act of 2022.